Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy
08:16am, Wednesday, 18'th Feb 2026
Nektar Therapeutics (NKTR) is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable im
Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of “Moderate Buy” from Analysts
02:24am, Wednesday, 18'th Feb 2026
Shares of Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports.
SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy
Can NKTR Stock Sustain Its 1,000% Rally?
09:30am, Friday, 13'th Feb 2026
Nektar stock has increased more than 100% within a week and has skyrocketed 1,000% from its 52-week low of $6.50, trading at around $71 as of February 13, 2026. The surge intensified following the com
Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume Following Analyst Upgrade
03:08am, Thursday, 12'th Feb 2026
Shares of Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) saw unusually-strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $135.00 to $165.00. HC W
Nektar Therapeutics Target of Unusually High Options Trading (NASDAQ:NKTR)
02:27am, Thursday, 12'th Feb 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) saw unusually large options trading on Tuesday. Stock investors purchased 5,080 call options on the company. This represents an increase of 145% co
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
10:23pm, Wednesday, 11'th Feb 2026
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock?
09:11am, Wednesday, 11'th Feb 2026
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Why Is Nektar Therapeutics Stock Gaining Wednesday?
07:35am, Wednesday, 11'th Feb 2026
Nektar Therapeutics (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
04:24pm, Tuesday, 10'th Feb 2026
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics Announces Proposed Public Offering
04:05pm, Tuesday, 10'th Feb 2026
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses obs
Critical Review: Polydex Pharmaceuticals (OTCMKTS:POLXF) and Nektar Therapeutics (NASDAQ:NKTR)
01:30am, Tuesday, 10'th Feb 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Polydex Pharmaceuticals (OTCMKTS:POLXF - Get Free Report) are both medical companies, but which is the better business? We will contrast the tw
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will
